×
We use cookies to ensure that we give you the best experience on our website.
If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again.
Click our cookies policy for information on how to change your cookie settings.
meta|Evidence
- COVID-19
Living meta-analysis and evidence synthesis of therapies for COVID19
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Interactive explorer of NMA results
Click on treatment name to display related network evidence
T vs. C
corticosteroids
remdesivir
convalescent plasma treatment
baricitinib
tofacitinib
casirivimab/imdevimab (Ronapreve)
interferon
tocilizumab
sarilumab
control
corticosteroids
---
1.78 1.17; 2.70
0.49 0.04; 6.03
1.12 0.99; 1.28
NA
NA
NA
0.64 0.17; 2.38
NA
0.98 0.93; 1.02
remdesivir
0.56 0.37; 0.86
---
0.28 0.02; 3.51
0.63 0.41; 0.98
NA
NA
NA
0.36 0.09; 1.43
NA
0.55 0.36; 0.84
convalescent plasma treatment
2.05 0.17; 25.25
3.64 0.28; 46.41
---
2.30 0.19; 28.43
NA
NA
NA
1.32 0.08; 22.35
NA
2.00 0.16; 24.66
baricitinib
0.89 0.78; 1.01
1.58 1.02; 2.44
0.44 0.04; 5.38
---
NA
NA
NA
0.57 0.15; 2.13
NA
0.87 0.77; 0.98
tofacitinib
NA
NA
NA
NA
---
NA
NA
NA
NA
NA
casirivimab/imdevimab (Ronapreve)
NA
NA
NA
NA
NA
---
NA
NA
NA
NA
interferon
NA
NA
NA
NA
NA
NA
---
NA
NA
NA
tocilizumab
1.56 0.42; 5.76
2.76 0.70; 10.91
0.76 0.04; 12.91
1.75 0.47; 6.50
NA
NA
NA
---
NA
1.52 0.41; 5.62
sarilumab
NA
NA
NA
NA
NA
NA
NA
NA
---
NA
control
1.02 0.98; 1.07
1.82 1.20; 2.76
0.50 0.04; 6.17
1.15 1.02; 1.30
NA
NA
NA
0.66 0.18; 2.43
NA
---
This project is supported by a grant of the French Ministry of Health (Hospital Clinical Research Program, PHRC-N) and self-funded by Hospices Civils de Lyon, CNRS UMR5558 LBBE University Lyon-1.
